CHANG NANCY T

SEC source: 0001193125-26-335224 · ownership.xml · derivative · entry 4

CHANG NANCY T · CIK 0001135041 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 480 shares

Expires 2035-02-23

F2 · derivative.exercise_price: These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera effected on July 12, 2026.

F2 · shares: These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera effected on July 12, 2026.

F3 · price: Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the "Merger Agreement"), by and among Galera, Obsidian Therapeutics, Inc. ("Obsidian"), Gazelle Parent, Inc. ("Parent"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent ("Obsidian Merger Sub"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Galera Merger Sub"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the "Galera Merger"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent.

F5 · price: At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an "In-the-Money Option"), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.

F3 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the "Merger Agreement"), by and among Galera, Obsidian Therapeutics, Inc. ("Obsidian"), Gazelle Parent, Inc. ("Parent"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent ("Obsidian Merger Sub"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Galera Merger Sub"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the "Galera Merger"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent.

F5 · derivative.exercise_date: At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an "In-the-Money Option"), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.

F2 · derivative.underlying_shares: These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera effected on July 12, 2026.

SEC source: 0001193125-26-335224 · ownership.xml · nonDerivative · entry 2

CHANG NANCY T · CIK 0001135041 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · shares: These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera effected on July 12, 2026.

F3 · price: Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the "Merger Agreement"), by and among Galera, Obsidian Therapeutics, Inc. ("Obsidian"), Gazelle Parent, Inc. ("Parent"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent ("Obsidian Merger Sub"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Galera Merger Sub"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the "Galera Merger"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent.

F4 · price: At the effective time of the Galera Merger (the "Galera Effective Time"), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the "Galera Exchange Ratio").

SEC source: 0001104659-26-084282 · tm2620606-7_4seq1.xml · nonDerivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,100

F1 · kind: Shares were sold to pay taxes upon the vesting of restricted stock units.

F2 · price: The price reported in column 4 is a weighted average sales price. These shares were sold at prices ranging from $3.33 to $3.335.

SEC source: 0001104659-26-071066 · tm2617014-4seq1.xml · derivative · entry 3

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 103,448 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock or its cash equivalent, as determined at the time of settlement by WTI.

F1 · derivative.exercise_date: On June 3, 2026, the reporting person's 103,448 restricted stock units, which were granted on June 3, 2025, vested, and the reporting person received 103,448 shares of common stock.

F1 · derivative.expiration_date: On June 3, 2026, the reporting person's 103,448 restricted stock units, which were granted on June 3, 2025, vested, and the reporting person received 103,448 shares of common stock.

SEC source: 0001104659-26-071066 · tm2617014-4seq1.xml · derivative · entry 2

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,972

Underlying: Common Stock · 35,972 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock or its cash equivalent, as determined at the time of settlement by WTI.

F3 · derivative.exercise_date: The restricted stock units will vest on the earlier of June 3, 2027, or the date of WTI's next annual shareholder meeting, subject to certain conditions.

F3 · derivative.expiration_date: The restricted stock units will vest on the earlier of June 3, 2027, or the date of WTI's next annual shareholder meeting, subject to certain conditions.

SEC source: 0001104659-26-071066 · tm2617014-4seq1.xml · nonDerivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock or its cash equivalent, as determined at the time of settlement by WTI.

F1 · acquired: On June 3, 2026, the reporting person's 103,448 restricted stock units, which were granted on June 3, 2025, vested, and the reporting person received 103,448 shares of common stock.

SEC source: 0001493152-26-026426 · ownership.xml · derivative · entry 3

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-05-22

F3 · derivative.exercise_date: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

SEC source: 0001493152-26-026426 · ownership.xml · nonDerivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 428,190

F1 · shares: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.

SEC source: 0001193125-26-335224 · ownership.xml · derivative · entry 3

CHANG NANCY T · CIK 0001135041 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 661,309 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 12, 2026, Galera Therapeutics, Inc. ("Galera") filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of Galera's board of directors, Galera may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Galera common stock calculated based on the Conversion Ratio (defined as 1,000 shares of Galera common stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On May 15, 2026, Galera effected a Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock had no expiration date.

F1 · derivative.exercise_date: On February 12, 2026, Galera Therapeutics, Inc. ("Galera") filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of Galera's board of directors, Galera may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Galera common stock calculated based on the Conversion Ratio (defined as 1,000 shares of Galera common stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On May 15, 2026, Galera effected a Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock had no expiration date.

F1 · derivative.expiration_date: On February 12, 2026, Galera Therapeutics, Inc. ("Galera") filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of Galera's board of directors, Galera may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Galera common stock calculated based on the Conversion Ratio (defined as 1,000 shares of Galera common stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On May 15, 2026, Galera effected a Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock had no expiration date.

SEC source: 0001193125-26-335224 · ownership.xml · nonDerivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,486,852

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 12, 2026, Galera Therapeutics, Inc. ("Galera") filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of Galera's board of directors, Galera may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Galera common stock calculated based on the Conversion Ratio (defined as 1,000 shares of Galera common stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On May 15, 2026, Galera effected a Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock had no expiration date.

SEC source: 0000905148-26-001622 · form4.xml · derivative · entry 2

CHANG NANCY T · CIK 0001135041 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 661.309

Underlying: Common Stock · 1,180,611 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 12, 2026, the Issuer filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Common Stock calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On April 7, 2026, the Issuer effected a partial Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock have no expiration date.

F1 · derivative.exercise_date: On February 12, 2026, the Issuer filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Common Stock calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On April 7, 2026, the Issuer effected a partial Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock have no expiration date.

F1 · derivative.expiration_date: On February 12, 2026, the Issuer filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Common Stock calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On April 7, 2026, the Issuer effected a partial Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock have no expiration date.

SEC source: 0000905148-26-001622 · form4.xml · nonDerivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,825,543

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 12, 2026, the Issuer filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Common Stock calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On April 7, 2026, the Issuer effected a partial Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock have no expiration date.

SEC source: 0001493152-25-027329 · ownership.xml · derivative · entry 3

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,643

Underlying: Common Stock · 39,643 shares

Expires 2035-11-21

F2 · derivative.exercise_date: The Stock Option will vest in thirty-six (36) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer and the terms of a Stock Option Agreement entered into to evidence the award.

SEC source: 0001104659-25-056883 · tm2517198-3_4seq1.xml · derivative · entry 3

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 73,892 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock or its cash equivalent, as determined at the time of settlement by WTI.

F1 · derivative.exercise_date: On June 3, 2025, the reporting person's 73,892 restricted stock units, which were granted on June 14, 2024, vested, and the reporting person received 73,892 shares of common stock.

F1 · derivative.expiration_date: On June 3, 2025, the reporting person's 73,892 restricted stock units, which were granted on June 14, 2024, vested, and the reporting person received 73,892 shares of common stock.

SEC source: 0001104659-25-056883 · tm2517198-3_4seq1.xml · derivative · entry 2

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,448

Underlying: Common Stock · 103,448 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock or its cash equivalent, as determined at the time of settlement by WTI.

F3 · derivative.exercise_date: The restricted stock units will vest on the earlier of June 3, 2026, or the date of WTI's next annual shareholder meeting, subject to certain conditions.

F3 · derivative.expiration_date: The restricted stock units will vest on the earlier of June 3, 2026, or the date of WTI's next annual shareholder meeting, subject to certain conditions.

SEC source: 0001104659-25-056883 · tm2517198-3_4seq1.xml · nonDerivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,652

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock or its cash equivalent, as determined at the time of settlement by WTI.

F1 · acquired: On June 3, 2025, the reporting person's 73,892 restricted stock units, which were granted on June 14, 2024, vested, and the reporting person received 73,892 shares of common stock.

SEC source: 0000905148-25-000786 · form4.xml · derivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Common Stock · 96,000 shares

Expires 2035-02-23

F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 substantially equal monthly installments measured from December 30, 2024, with the first installment having vested on January 30, 2025, subject to the Reporting Person's continuing service on the Board as a Non-Employee Director through each vesting date.

SEC source: 0000905148-25-000010 · form4.xml · derivative · entry 2

CHANG NANCY T · CIK 0001135041 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,841.92

Underlying: Common Stock · 1,841,920 shares

Expires not disclosed

F3 · derivative.exercise_price: No earlier than twelve months following the Closing, but no later than eighteen months following the Closing, the Issuer will submit to its stockholders for their consideration the approval of the conversion of the Series B Preferred Stock into shares of Common Stock (the "Conversion Proposal"). Following stockholder approval of the Conversion Proposal, each share of Series B Preferred Stock will be convertible into 1,000 shares of Common Stock at any time at the option of the holder thereof, subject to certain limitations. These shares of Series B Preferred Stock have no expiration date.

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated December 30, 2024 (the "Merger Agreement") by and among Galera Therapeutics, Inc., a Delaware corporation (the "Issuer"), Grape Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Grape Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Nova Pharmaceuticals, Inc., a Delaware corporation ("Nova"), on December 30, 2024 (the "Closing"), the Issuer acquired Nova. In accordance with the Merger Agreement, First Merger Sub merged with and into Nova (the "First Merger"), with Nova surviving as a wholly owned subsidiary of the Issuer. Following the First Merger and as part of the same overall transaction as the First Merger, Nova will merge with and into Second Merger Sub (the "Second Merger" and, together with the First Merger, the "Merger"), with Second Merger Sub being the surviving entity of the Second Merger.

F2 · kind: At the Closing, the Reporting Person acquired these shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") in exchange for shares of Common Stock of Nova held immediately prior to the Closing, which were automatically converted into a number of shares of Series B Preferred Stock at an exchange ratio of 177.9117.

F2 · price: At the Closing, the Reporting Person acquired these shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") in exchange for shares of Common Stock of Nova held immediately prior to the Closing, which were automatically converted into a number of shares of Series B Preferred Stock at an exchange ratio of 177.9117.

F3 · derivative.exercise_date: No earlier than twelve months following the Closing, but no later than eighteen months following the Closing, the Issuer will submit to its stockholders for their consideration the approval of the conversion of the Series B Preferred Stock into shares of Common Stock (the "Conversion Proposal"). Following stockholder approval of the Conversion Proposal, each share of Series B Preferred Stock will be convertible into 1,000 shares of Common Stock at any time at the option of the holder thereof, subject to certain limitations. These shares of Series B Preferred Stock have no expiration date.

F3 · derivative.expiration_date: No earlier than twelve months following the Closing, but no later than eighteen months following the Closing, the Issuer will submit to its stockholders for their consideration the approval of the conversion of the Series B Preferred Stock into shares of Common Stock (the "Conversion Proposal"). Following stockholder approval of the Conversion Proposal, each share of Series B Preferred Stock will be convertible into 1,000 shares of Common Stock at any time at the option of the holder thereof, subject to certain limitations. These shares of Series B Preferred Stock have no expiration date.

SEC source: 0000905148-25-000010 · form4.xml · nonDerivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,644,932

SEC source: 0001104659-24-072857 · tm2417461-3_4seq1.xml · derivative · entry 3

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 38,760 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock or its cash equivalent, as determined at the time of settlement by WTI.

F1 · derivative.exercise_date: On June 17, 2024, the reporting person's 38,760 restricted stock units, which were granted on July 3, 2023, vested, and the reporting person received 38,760 shares of common stock.

F1 · derivative.expiration_date: On June 17, 2024, the reporting person's 38,760 restricted stock units, which were granted on July 3, 2023, vested, and the reporting person received 38,760 shares of common stock.

SEC source: 0001104659-24-072857 · tm2417461-3_4seq1.xml · nonDerivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock or its cash equivalent, as determined at the time of settlement by WTI.

F1 · acquired: On June 17, 2024, the reporting person's 38,760 restricted stock units, which were granted on July 3, 2023, vested, and the reporting person received 38,760 shares of common stock.

SEC source: 0001104659-24-072857 · tm2417461-3_4seq1.xml · derivative · entry 2

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,892

Underlying: Common Stock · 73,892 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock or its cash equivalent, as determined at the time of settlement by WTI.

F3 · derivative.exercise_date: The restricted stock units will vest on the earlier of June 14, 2025, or the date of WTI's next annual shareholder meeting, subject to certain conditions.

F3 · derivative.expiration_date: The restricted stock units will vest on the earlier of June 14, 2025, or the date of WTI's next annual shareholder meeting, subject to certain conditions.

SEC source: 0001104659-23-078813 · tm2320049-3_4seq1.xml · derivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,760

Underlying: Common Stock · 38,760 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WTI common stock or its cash equivalent.

F2 · derivative.exercise_date: The restricted stock units will vest on the earlier of July 3, 2024, or the date of WTI's next annual shareholder meeting, subject to certain conditions.

F2 · derivative.expiration_date: The restricted stock units will vest on the earlier of July 3, 2024, or the date of WTI's next annual shareholder meeting, subject to certain conditions.

SEC source: 0000899243-17-024257 · doc4.xml · derivative · entry 3

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2027-06-08

F2 · price: The option was canceled immediately prior to the Merger in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.

F3 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger").

SEC source: 0000899243-17-024257 · doc4.xml · derivative · entry 2

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2025-06-11

F2 · price: The option was canceled immediately prior to the Merger in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.

F1 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.

SEC source: 0000899243-17-024257 · doc4.xml · nonDerivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0000880771-17-000099 · certent-form4.xml · derivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director · Board Member

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-06-08

F1 · security: Granted under the Issuer's 2015 Equity Incentive Plan.

F2 · derivative.exercise_date: Each option shall vest and become exercisable at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant except that, in the event of a change in control, any unexercisable or unvested portions of outstanding options shall be immediately exercisable and vested in full as of the date ten (10) days prior to the change in control, regardless of whether the option is assumed or substituted for by the acquirer.

SEC source: 0000880771-16-000193 · certent-form4.xml · derivative · entry 4

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,333 shares

Expires 2023-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Granted under the Issuer's 2005 Equity Incentive Plan.

F3 · derivative.exercise_date: Shares will become exercisable in three equal annual installments beginning on the first anniversary of the date of grant, subject to the Outside Director's continuous service on Issuer's Board of Directors.

SEC source: 0000880771-16-000193 · certent-form4.xml · derivative · entry 3

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,648 shares

Expires 2024-06-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Granted under the Issuer's 2005 Equity Incentive Plan.

F2 · derivative.exercise_date: Each option shall vest and become exercisable at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant except that, in the event of a change in control, any unexercisable or unvested portions of outstanding options shall be immediately exercisable and vested in full as of the date ten (10) days prior to the change in control, regardless of whether the option is assumed or substituted for by the acquirer.

SEC source: 0000880771-16-000193 · certent-form4.xml · nonDerivative · entry 2

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000880771-16-000193 · certent-form4.xml · nonDerivative · entry 1

CHANG NANCY T · CIK 0001135041 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.